ArticleBioTechniques2018
Luciferase complementation based-detection of G-protein-coupled receptor activity.
Article in BioTechniques, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Development and characterization of new tools for detecting poly(ADP-ribose) in vitro and in vivo.eLife · 2022Article
- Luciferase Complementation Approaches to Measure GPCR Signaling Kinetics and Bias.Methods in molecular biology (Clifton, N.J.) · 2021Article
- NanoBiT Complementation to Monitor Agonist-Induced Adenosine ASLAS discovery : advancing life sciences R & D · 2020Article
- Design and development of stapled transmembrane peptides that disrupt the activity of G-protein-coupled receptor oligomers.The Journal of biological chemistry · 2019Article
- Development and Applications of Bioluminescent and Chemiluminescent Reporters and Biosensors.Annual review of analytical chemistry (Palo Alto, Calif.) · 2019Review
- A dynamic and screening-compatible nanoluciferase-based complementation assay enables profiling of individual GPCR-G protein interactions.The Journal of biological chemistry · 2019Article
- Pharmacological profiling of sigma 1 receptor ligands by novel receptor homomer assays.Neuropharmacology · 2018Article
- A general method for quantifying ligand binding to unmodified receptors using Gaussia luciferase.The Journal of biological chemistryArticle
- A novel luminescence-based β-arrestin recruitment assay for unmodified receptors.The Journal of biological chemistryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Protein complementation assays (PCA) are used as pharmacological tools, enabling a wide array of applications, ranging from studies of protein-protein interactions to second messenger effects. Methods to detect activities of G protein-coupled receptors (GPCRs) have particular relevance for drug screening. Recent development of an engineered luciferase NanoLuc created the possibility of generating a novel PCA, which in turn could open a new avenue for developing drug screening assays. Here we identified a novel split position for NanoLuc and demonstrated its use in a series of fusion constructs to detect the activity of GPCRs. The split construct can be applied to a variety of pharmacological screening systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.